 |
MacDougall Biomedical Communications represents Cambridge-based Momenta Pharmaceuticals as it agrees to be acquired by Johnson & Johnson for $6.5B cash.
It's the biggest pharmaceuticals deal of the year, according to Bloomberg, and the latest sign that drug companies are "looking for ways to bulk up even as the coronavirus pandemic upends other businesses."
Craig Wheeler, CEO of Momenta, called J&J the right company to advance its portfolio of drug candidates for autoimmune and rare diseases.
"J&J’s leadership in immunology, extensive capabilities, and global reach, as well as its alignment with our vision of pioneering therapies for complex diseases, is a strong fit for our company and our portfolio,” he said.
The deal will be completed by the end of the year
MacDougall Biomedical managing director Karen Sharma, a veteran of Schwartz Communications and Newgrange Consulting, represents Momenta.
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
Uber’s Mike Lucarelli is moving to NXP Semiconductors as senior VP-investor relations.
